stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Revenue growth
Teva Pharmaceutical Industries Ltd.'s revenue growth over the twelve months to 30 September 2026 was 2.71%, down 1.6 percentage points from fiscal 2025 (4.32%). Over the past ten years it has ranged from −18.4% (fiscal 2018) to 11.5% (fiscal 2016); the current reading is higher than 73% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 4.32% | (0.08) |
| FY2024 | 4.40% | (1.77) |
| FY2023 | 6.17% | 12.17 |
| FY2022 | −6.00% | (1.31) |
| FY2021 | −4.69% | (3.34) |
| FY2020 | −1.35% | 6.22 |
| FY2019 | −7.57% | 10.81 |
| FY2018 | −18.4% | (20.58) |
| FY2017 | 2.20% | (9.25) |
| FY2016 | 11.5% | 14.51 |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −1.90% | (1.09) |
| Jun 2026 | −0.81% | (3.15) |
| Mar 2026 | 2.34% | (9.06) |
| Dec 2025 | 11.4% | 7.98 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 38.0% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. compare | 4.27% |
| TEVA Teva Pharmaceutical Industries Ltd. | 2.71% |
| UTHR United Therapeutics Corporation compare | 1.89% |
| ZTS Zoetis Inc. compare | 1.58% |
| TAK Takeda Pharmaceutical Co. compare | 0.66% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement